Palbociclib
Palbociclib is an approved active ingredient.
Drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer
What it is used for
- Secondary neoplasm
- Rare breast tumor
- Head and neck squamous cell carcinoma
- Breast neoplasm
- Neoplasm
IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy; or o…
Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have…
How it works
- CDK6/cyclin D1 inhibitor
- Cyclin-dependent kinase 4/cyclin D1 inhibitor
Common side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: • Neutropenia • ILD/Pneumonitis Most common adverse reactions (incidence ≥20%) in combination with either letrozole or fulvestrant, including laboratory abnormalities, were white blood cell count decreased, neutrophils…
Pregnancy and breastfeeding
Based on findings from animal studies and its mechanism of action, IBRANCE can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk.
Interactions
- Carbamazepine
- Ciclosporin
- Clarithromycin
- Enzalutamide
- Everolimus
- Fentanyl
- Indinavir anhydrous
- Midazolam
- Nelfinavir
- Phenytoin
- Posaconazole
- Quinidine
- Rifampicin
- Ritonavir
- Saquinavir
- Sirolimus
- Voriconazole
Brand names
United States
Ibrance
European Union
Ibrance · Palbociclib Viatris
Canada
Ibrance · Nat-Palbociclib · Pms-Palbociclib · Taro-Palbociclib
Approval status
- US Food and Drug Administration
- prescription · since 2015
- European Medicines Agency
- authorised · since 2016
- Health Canada
- prescription · marketed
- First approval anywhere
- 2015
Codes
- ATC
- L01EF01
- RxNorm CUI
- 1601374
- ChEMBL
- CHEMBL189963
- PubChem CID
- 5330286
- UNII
- G9ZF61LE7G
- Wikidata
- Q15269707
Frequently asked questions
What is Palbociclib used for?
Palbociclib is used for: Secondary neoplasm, Rare breast tumor, Head and neck squamous cell carcinoma, Breast neoplasm, and Neoplasm.
What are the brand names of Palbociclib?
Brand names of Palbociclib include Ibrance, Palbociclib Viatris, Nat-Palbociclib, Pms-Palbociclib, and Taro-Palbociclib.
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)